Vivoryon Therapeutics NV (FRA:05Y) Short-Term Capital Lease Obligation : €0.04 Mil (As of Dec. 2023)

View and export this data going back to 2014. Start your Free Trial

What is Vivoryon Therapeutics NV Short-Term Capital Lease Obligation?

Vivoryon Therapeutics NV's Short-Term Capital Lease Obligation for the quarter that ended in Dec. 2023 was €0.04 Mil.

Vivoryon Therapeutics NV's quarterly Short-Term Capital Lease Obligation declined from Dec. 2022 (€0.09 Mil) to Jun. 2023 (€0.08 Mil) and declined from Jun. 2023 (€0.08 Mil) to Dec. 2023 (€0.04 Mil).

Vivoryon Therapeutics NV's annual Short-Term Capital Lease Obligation increased from Dec. 2021 (€0.09 Mil) to Dec. 2022 (€0.09 Mil) but then declined from Dec. 2022 (€0.09 Mil) to Dec. 2023 (€0.04 Mil).

Vivoryon Therapeutics NV Short-Term Capital Lease Obligation Historical Data

The historical data trend for Vivoryon Therapeutics NV's Short-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vivoryon Therapeutics NV Short-Term Capital Lease Obligation Chart

Vivoryon Therapeutics NV Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Short-Term Capital Lease Obligation

Get a 7-Day Free Trial

0.09

0.04

Vivoryon Therapeutics NV Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Short-Term Capital Lease Obligation	Get a 7-Day Free Trial															0.09	0.09	0.09	0.08	0.04

Vivoryon Therapeutics NV Short-Term Capital Lease Obligation Explanation

Short-Term Capital Lease Obligation represents the total amount of Long-Term Capital Lease Obligation that must be paid within the next accounting period. Capital lease obligations are contractual obligations that arise from obtaining the use of property or equipment via a capital lease contract.

Vivoryon Therapeutics NV Short-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Vivoryon Therapeutics NV's Short-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Vivoryon Therapeutics NV (FRA:05Y) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vivoryon Therapeutics NV (FRA:05Y) » Definitions » Short-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

VVY:Netherlands

Address

Weinbergweg 22, Halle, SN, DEU, 06120

Website

https://www.vivoryon.com

Vivoryon Therapeutics NV is a Germany-based biopharmaceutical company engaged in the activities of research and development, preclinical and clinical trials. It is focused on the development of therapeutic products for the treatment of Alzheimer's disease and cancer. The company's pipeline products include PQ912 and PQ1565. Geographically, the majority is from Greater China.

Vivoryon Therapeutics NV (FRA:05Y) Headlines

No Headlines